The Global Reporting Initiative (GRI) is introducing a new feature called ‘fast track’, which will give reporting organizations the option to accelerate the review of their draft reports. GRI is fast ...
GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, July 31, 2025 ...
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm - suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities ...
Cash runway expected to fund operations into Q2 2025, including interim data readout from GRI-0621 LA JOLLA, CA, March 17, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the ...
Most organizations still treat sustainability reporting as a communications exercise. But sustainability impacts are created ...
The Global Reporting Initiative released a report Wednesday urging companies to take a due diligence approach in their sustainability efforts. Processing Content The paper explains how due diligence ...
The first thing I'd like to say about the response GRI provided (September 21, 2011) is Thank You! There are many demands on GRI’s time and attention, I’m sure, and to receive the kind of response we ...
LA JOLLA, CA, May 14, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell ...
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, Sept. 11, 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results